GO
Loading...

Bristol-Myers Squibb Co

More

  • Jan 30- Eli Lilly and Co cut its 2015 revenue forecast, issued earlier this month, as the U.S. drugmaker expects a bigger hit from a stronger dollar. Large U.S. healthcare companies such as Johnson& Johnson, Pfizer Inc and Bristol-Myers Squibb Co have in the past weeks issued 2015 earnings forecasts below Wall Street expectations, citing the stronger dollar.

  • UPDATE 1-U.S. FDA approves Bristol-Myers, J&J HIV pills Thursday, 29 Jan 2015 | 6:35 PM ET

    Jan 29- The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors- one made by Bristol-Myers Squibb Co and the other by Johnson& Johnson- both with a boosting agent produced by Gilead Sciences Inc.. Bristol-Myers said its drug, Evotaz, is a once-daily pill containing Reyataz, also known as atazanavir, a...

  • Final Glance: Pharmaceuticals companies Thursday, 29 Jan 2015 | 6:14 PM ET

    Baxter International Inc. rose $1.22 or 1.7 percent, to $71.38. Bristol-Myers Squibb Co. fell$. 19 or. 3 percent, to $61.14. Hospira rose$. 13 or. 2 percent, to $64.78.

  • U.S. FDA approves Bristol-Myers' HIV drug Thursday, 29 Jan 2015 | 5:44 PM ET

    Jan 29- The U.S. Food and Drug Administration has approved the sale of Evotaz, a once-daily combination pill to treat HIV made by Bristol-Myers Squibb Co, the company said on Thursday. The new drug combines Reyataz, also known as atazanavir, a Bristol-Myers' protease inhibitor, with cobicistat, a boosting agent produced by Gilead Sciences Inc..

  • Abbott CEO losing no sleep over stronger dollar Thursday, 29 Jan 2015 | 3:15 PM ET

    Jan 29- Abbott Laboratories' chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics. Half of its sales are in emerging markets, like China and...

  • Midday Glance: Pharmaceuticals companies Thursday, 29 Jan 2015 | 1:23 PM ET

    Baxter International Inc. rose$. 68 or 1.0 percent, to $70.84. Bristol-Myers Squibb Co. fell$. 62 or 1.0 percent, to $60.72. Hospira fell$. 68 or 1.1 percent, to $63.97.

  • Jan 29- Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, forecast 2015 sales and earnings below analysts' expectations, becoming the latest U.S. healthcare company to warn about a strengthening dollar. The company expects profit to be hit by 58 cents in 2015. It forecast $7.22 to $7.40, excluding special items, below analysts'...

  • Early Glance: Pharmaceuticals companies Thursday, 29 Jan 2015 | 10:40 AM ET

    Baxter International Inc. rose$. 57 or. 8 percent, to $70.73. Bristol-Myers Squibb Co. fell$. 77 or 1.3 percent, to $60.56. Hospira fell$. 49 or. 8 percent, to $64.16.

  • Final Glance: Pharmaceuticals companies Wednesday, 28 Jan 2015 | 6:07 PM ET

    Baxter International Inc. fell$. 50 or. 7 percent, to $70.16. Bristol-Myers Squibb Co. fell$. 66 or 1.1 percent, to $61.33. Hospira fell$. 84 or 1.3 percent, to $64.65.

  • Midday Glance: Pharmaceuticals companies Wednesday, 28 Jan 2015 | 1:21 PM ET

    Baxter International Inc. rose$. 17 or. 2 percent, to $70.83. Bristol-Myers Squibb Co. rose$. 48 or. 8 percent, to $62.47. Hospira fell$. 21 or. 3 percent, to $65.28.

  • Early Glance: Pharmaceuticals companies Wednesday, 28 Jan 2015 | 10:41 AM ET

    Baxter International Inc. rose$. 27 or. 4 percent, to $70.93. Bristol-Myers Squibb Co. rose$. 66 or 1.1 percent, to $62.65. Hospira rose$. 30 or. 5 percent, to $65.79.

  • *CEO says Roche committed to Switzerland despite franc rise. While cross-town rival Novartis has said it will review its Swiss cost base, Roche Chief Executive Severin Schwan said his company had no plans to move operations. "I continue to believe that Switzerland and Basel offer a very good framework for our business," Schwan told reporters.

  • Final Glance: Pharmaceuticals companies Tuesday, 27 Jan 2015 | 6:08 PM ET

    Baxter International Inc. fell$. 22 or. 3 percent, to $70.66. Bristol-Myers Squibb Co. fell$. 47 or. 8 percent, to $61.99. Hospira fell $1.01 or 1.5 percent, to $65.49.

  • *Apple, P&G, Stryker also see headwinds. NEW YORK, Jan 27- A slew of U.S. multinational companies, from DuPont to Procter& Gamble, showed that a strong U.S. dollar hurt their earnings, and several blue-chip exporters said the situation will get worse if the greenback holds its strength. The pain is hitting multiple sectors, including industrial companies such as 3 M Co,...

  • *Apple also at risk; Microsoft shares plummet on currency concern. NEW YORK, Jan 27- A slew of U.S. multinational companies from DuPont to Microsoft Corp showed that a strong U.S. dollar is hammering their earnings, with several blue chip exporters predicting the situation will get worse if the greenback holds its strength. The pain is hitting multiple sectors...

  • Midday Glance: Pharmaceuticals companies Tuesday, 27 Jan 2015 | 1:36 PM ET

    Baxter International Inc. fell$. 10 or. 1 percent, to $70.78. Bristol-Myers Squibb Co. fell$. 61 or 1.0 percent, to $61.85. Hospira fell$. 69 or 1.0 percent, to $65.81.

  • Early Glance: Pharmaceuticals companies Tuesday, 27 Jan 2015 | 10:25 AM ET

    Baxter International Inc. fell$. 27 or. 4 percent, to $70.61. Bristol-Myers Squibb Co. fell$. 81 or 1.3 percent, to $61.65. Hospira fell$. 44 or. 7 percent, to $66.06.

  • Jan 27- Bristol-Myers Squibb Co on Tuesday said profits could fall as much as 16 percent in 2015, a worse forecast than Wall Street had expected, as the stronger dollar takes a toll on U.S. drugmakers. Bristol-Myers, whose shares fell almost 2 percent in premarket trading, said it earned $13 million, or 1 cent per share, in the fourth quarter. Revenue fell 4 percent to...

  • Bristol-Myers quarterly profit beats forecasts Tuesday, 27 Jan 2015 | 7:56 AM ET

    Jan 27- Bristol-Myers Squibb Co reported higher-than-expected quarterly earnings, helped by surprisingly strong sales of its hepatitis C drugs and its Eliquis blood clot preventer. The U.S. drugmaker on Tuesday said it earned $13 million, or 1 cent per share, in the fourth quarter. Revenue fell 4 percent to $4.26 billion, coming in above Wall Street expectations...

  • NEW YORK— Bristol-Myers Squibb Co. barely broke even in the fourth quarter, due to a whopping pension charge and slightly lower prescription drug sales, but the drugmaker easily beat Wall Street's muted profit expectations. Giovanni Caforio, 50, will take over running the company on May 5, the company said last week. The company took a $740 million charge for...